Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs

E.A.B. and I.P. are co-inventors on NIH-owned issued patents and patent applications for CD4-PE and 3B3-PE. This work was supported in part by the Intramural Program of the NIH (National Institute of Allergy and Infectious Diseases; National Cancer Institute), including the NIH Intramural AIDS Targeted Antiviral Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.